A hybrid
cell line resulting from the fusion of a specific
antibody -producing spleen cell (lymphocyte) with a myeloma cell, which has the growth characteristics of the myeloma component and the
antibody-secreting characteristics of the lymphocyte, and will multiply to become a source of pure
monoclonal antibody.
Source:
PAC, 1992, 64, 143
(Glossary for chemists of terms used in biotechnology (IUPAC Recommendations 1992))
on page 156
